How much funding has Kalaris Therapeutics raised?

Kalaris Therapeutics has raised $53.8M in total funding, most recently a Corporate Round.

Who are Kalaris Therapeutics's investors?

Kalaris Therapeutics's investors include ADAR1 Capital, Invus.

Where is Kalaris Therapeutics headquartered?

Kalaris Therapeutics is headquartered in Berkeley Heights, United States.

What industry is Kalaris Therapeutics in?

Kalaris Therapeutics operates in Biotech, Healthcare.

Kalaris Therapeutics

Acquired

Your vision, our mission

Public · Berkeley Heights, United States · $53.8M raised

Biotech

Healthcare

Headquarters: Berkeley Heights
Business Model: B2B
Website: kalaristx.com
Total Funding: $53.8M

Last Round: $50.0M Corporate RoundDec 2025
Rounds: 2
Type: Public

About

Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing treatments for prevalent retinal diseases with major unmet medical needs, including wet AMD, diabetic eye disease, and retinal vein occlusion. Its lead asset, TH103, is an investigational dual-targeting biologic designed for extended intraocular retention and enhanced VEGF inhibition, aiming to reduce the frequent clinic visits current therapies require. Kalaris is headquartered in Berkeley Heights, New Jersey, and is backed by veteran biopharma investors.

Summary

Kalaris Therapeutics is a Biotech company based in Berkeley Heights, United States. It has raised $53.8M in total across 2 rounds, most recently a $50.0M Corporate Round round in Dec 2025. Investors include ADAR1 Capital and Invus.